AETERNA ZENTARIS INC.

AETERNA ZENTARIS

Pharmaceutical preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of hematological diseases, pharmaceutical preparations used for the treatment of age-related diseases, pharmaceutical preparations used for the treatment of ophtalmological disorders, pharmaceutical preparations used for the treatment of reproductive system disorders, pharmaceutical preparations used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparations used for the treatment of benign prostatic hyperplasia (BPH), pharmaceutical preparations used for the treatment of tropical diseases, pharmaceutical preparations used for the treatment of infectious disease, pharmaceutical preparations used for the treatment of leishmaniasis, pharmaceutical preparations used for the treatment of obesity, pharmaceutical preparations used for the treatment of diabetes and disorders related to diabetes, pharmaceutical preparations containing conjugated and non-conjugated cytotoxic products used to selectively and specifically target certain types of cancer; pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on LHRH antagonists platform used for the treatment of certain types of cancer and endocrine disorders, pharmaceutical preparations based on bombesin antagonist platform used for the treatment of certain types of cancer, pharmaceutical preparations based on inhibitors of the Akt pathway used for the treatment of certain types of cancer, pharmaceutical preparations based on angiogenesis inhibitors platform with multiple mechanisms of action used for the treatment of certain types of cancer, pharmaceutical preparations used to induce apoptosis, pharmaceutical preparations used to stimulate growth hormone secretagogue (GHS);